Is Pro-Dex, Inc. overvalued or undervalued?

As of 1 May 2025, Pro-Dex, Inc. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued based on its strong financial metrics. Key ratios include a P/E ratio of 16, an EV to EBITDA of 11.51, and a PEG ratio of 0.18, indicating significant growth potential relative to its price.
When compared to peers, Pro-Dex, Inc. has a more favorable P/E ratio than Cardiff Oncology, Inc., which does not qualify with a P/E of -5.0384, and Wrap Technologies, Inc., which has a P/E of -5.3865. The company's return over the past year stands at an impressive 122.57%, significantly outperforming the S&P 500's 10.26% return, further reinforcing its undervaluation narrative.